Targeting IL-6 or progranulin or both through sortilin could potentially be a new treatment approach for breast cancer patients with elevated progranulin and/or IL-6 levels, further emphasizing sortilin as an important therapeutic target for treating breast cancer. Here, SORT1 is linked to breast cancer.